NeuHyll Therapeutics

NeuHyll Therapeutics is a preclinical-stage biotechnology company focused on the development of small molecule therapeutics for neurodegenerative disorders. The company's core technology targets the accumulation of hyaluronan fragments in the brain, which are known to inhibit the repair of myelin and contribute to cognitive decline. By developing potent and selective hyaluronidase inhibitors, NeuHyll aims to promote remyelination and provide neuroprotective benefits for patients with Multiple Sclerosis and Alzheimer's disease. The company's approach represents a novel strategy in regenerative medicine for the central nervous system. NeuHyll is currently advancing its lead candidates through preclinical studies to establish safety and efficacy for future clinical trials.